Repositioning Candidate Details
| Candidate ID: | R0282 |
| Source ID: | DB00795 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Sulfasalazine |
| Synonyms: | 2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)benzoic acid; 2-Hydroxy-5-[4-(pyridin-2-ylsulfamoyl)-phenylazo]-benzoic acid; 4-(Pyridyl-2-amidosulfonyl)-3'-carboxy-4'-hydroxyazobenzene; 5-((p-(2-Pyridylsulfamoyl)phenyl)azo)salicylic acid; 5-(4-(2-Pyridylsulfamoyl)phenylazo)-2-hydroxybenzoic acid; 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid; Azopyrin; Salazosulfapyridine; Salicylazosulfapyridine; Sulfasalazine |
| Molecular Formula: | C18H14N4O5S |
| SMILES: | OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1 |
| Structure: |
|
| DrugBank Description: | A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see mesalamine) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907) |
| CAS Number: | 599-79-1 |
| Molecular Weight: | 398.393 |
| DrugBank Indication: | For the treatment of Crohn's disease and rheumatoid arthritis as a second-line agent. |
| DrugBank Pharmacology: | Sulfasalazine is an anti-inflammatory indicated for the treatment of ulcerative colitis and rheumatoid arthritis. |
| DrugBank MoA: | The mode of action of Sulfasalazine or its metabolites, 5-aminosalicylic acid (5-ASA) and sulfapyridine (SP), is still under investigation, but may be related to the anti-inflammatory and/or immunomodulatory properties that have been observed in animal and <i>in vitro</i> models, to its affinity for connective tissue, and/or to the relatively high concentration it reaches in serous fluids, the liver and intestinal walls, as demonstrated in autoradiographic studies in animals. In ulcerative colitis, clinical studies utilizing rectal administration of Sulfasalazine, SP and 5-ASA have indicated that the major therapeutic action may reside in the 5-ASA moiety. The relative contribution of the parent drug and the major metabolites in rheumatoid arthritis is unknown. |
| Targets: | Arachidonate 5-lipoxygenase inhibitor; Prostaglandin G/H synthase 2 inhibitor; Prostaglandin G/H synthase 1 inhibitor; Peroxisome proliferator-activated receptor gamma agonist; Inhibitor of nuclear factor kappa-B kinase subunit alpha inhibitor; Inhibitor of nuclear factor kappa-B kinase subunit beta inhibitor; Cystine/glutamate transporter inhibitor; Acetyl-CoA acetyltransferase, mitochondrial inhibitor; Thromboxane-A synthase antagonist; Phospholipase A2 antagonist |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I15 | 1290 | Bone disease | A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function. http://en.wikipedia.org/wiki/Bone_disease | disease of anatomical entity/ musculoskeletal system disease/connective tissue disease | Details |